Hunter vs Farmer in Pharma Services BD: Why Misreading the Difference Costs You 12 Months

The hunter/farmer distinction is one of the oldest frameworks in sales hiring. Most BD leaders would tell you they understand it. Most job briefs in pharma services suggest otherwise.

Across CDMO and CRO hiring, the misread between these two profiles is one of the most consistent and costly mistakes we see. The consequences aren't visible immediately, which is partly why it keeps happening. By the time the problem surfaces, the organisation has already lost the better part of a year.

‍

What the distinction actually means in practice

At a surface level, everyone agrees: hunters open new logos, farmers grow and retain existing accounts. The issue is that both profiles can sound identical on paper, especially in pharma services where most candidates have done elements of both.

A farmer in pharma services is exceptionally good at deepening relationships within an existing client base, navigating procurement and scientific stakeholders simultaneously, expanding scope, and protecting revenue that would otherwise erode. They're responsive, technically fluent, and comfortable playing a long game within accounts where trust is already established.

A hunter's entire commercial psychology is oriented differently. They're motivated by the blank page. Cold pipeline, new relationships, organisations that haven't worked with you before. They have a different tolerance for rejection, a different cadence for prospecting, and a different relationship with uncertainty. They don't need the warmth of existing relationships to stay motivated.

Neither is better. They're built for different jobs. The problem is that pharma services organisations, particularly those with complex service offerings in drug delivery or biologics manufacturing, have a structural tendency to misidentify which one they actually need.

‍

Why pharma services gets this wrong more than most sectors

The length of the sales cycle distorts everything. In pharma services, a first conversation and a signed MSA can be separated by 18 months or more. That creates two problems simultaneously.

First, it means a poor hire takes a very long time to show up as a poor hire. A farmer placed into a new logo remit will often look reasonable for the first six to nine months. They'll be nurturing conversations, attending conferences, building familiarity with a handful of prospects. The absence of closed pipeline can be rationalised. It's only when the 12-month mark arrives with no new accounts converted that the real shape of the problem becomes clear.

Second, the technical complexity of the offering creates a hiring bias towards sector familiarity. A candidate who can speak fluently about drug delivery platforms, formulation development, or GMP manufacturing tends to attract disproportionate confidence from hiring managers. That technical fluency gets mistaken for commercial drive. They're not the same thing. A candidate who deeply understands your service lines but whose natural orientation is towards relationship maintenance rather than prospecting will not build new pipeline, regardless of how credible they sound in interview.

The PE-backed CDMO context sharpens this further. In a platform CDMO that has acquired several manufacturing sites and is now under pressure to demonstrate commercial momentum, a farmer in a BD Director role doesn't just underperform. They actively delay pipeline in a way that creates distorted perception at board level. The CRO is typically showing its commercial health through new logo wins and mandate diversity. If the BD function is producing relationship activity without conversion, the board's read of commercial health will be wrong. By the time that's corrected, the cost includes the lag time, the re-hire, and in some cases the lost window with prospects who have since committed to a competitor.

‍

How the hiring process needs to change

The brief is usually where this goes wrong first. A job specification that reads "strong sector network, proven track record in pharma services BD, experience managing complex accounts" is describing a candidate pool, not a profile. It will attract both hunters and farmers in equal measure and provide no mechanism for distinguishing between them.

Writing a brief that attracts the right profile means being explicit about what success looks like in year one. If the role is new logo generation, the brief should say that. It should specify what new logo volume looks like in this organisation's commercial model, what the prospecting motion is, and what the commission structure rewards. Farmers will self-select out. Hunters will lean in.

The interview process needs to do something different from the standard competency walkthrough. Asking a candidate to walk you through their biggest deal will tell you very little about whether they're a hunter or farmer. The questions that surface it are more specific. Ask them to describe the last time they built pipeline from zero. Ask what percentage of their last role's revenue came from accounts they personally originated versus accounts they inherited. Ask how they approach a prospect that has never worked with your organisation and has an established relationship with a competitor. The answers to those questions, and the energy with which they're delivered, will tell you more than CV credentials.

Reference checks need to carry this focus too. The question to ask previous managers isn't whether the candidate was a strong commercial performer. It's what the nature of their pipeline looked like, and whether they were more effective opening new relationships or developing existing ones.

‍

The cost of getting it wrong

One anonymised example illustrates the pattern clearly enough. A PE-backed CDMO in a growth phase hired a BD Director with strong sector credentials and an impressive network across mid-size pharma. Twelve months in, the account management metrics looked healthy. Existing clients were satisfied and scope had expanded in two accounts. New logo pipeline was minimal. The individual had oriented entirely towards the existing commercial base because that's where their strengths lay and, in the absence of a clearly defined new logo mandate, that's where the organisation had implicitly let them focus.

The eventual outcome was a mutual exit, a re-hire process that took four months, and a 16-month lag before a hunter profile was in role and generating early-stage pipeline. The cost wasn't just financial. The board's confidence in the commercial function had been shaken, and the new hire was working to rebuild internal credibility alongside external pipeline.

That outcome was entirely avoidable. The organisation had the candidate's reference base, their deal history, and twelve months of interview time available to them. The signals were there. The interview process wasn't designed to surface them.

The hunter/farmer framework isn't a piece of HR theory. In pharma services, where sales cycles are long, technical credibility is high, and the pressure for commercial momentum is acute, it's one of the most practically important distinctions in BD hiring. The organisations that build it into their process early avoid a category of mistake that is expensive, slow to surface, and entirely predictable in hindsight.